Rising incidence of gene expression changes due to chemical modifications in DNA or chromatin is the major factor driving the growth of epigenetics drugs and diagnostic technologies market. Epigenetics is a regulatory method which controls the gene expressions without changing the gene sequence. The epigenetic process includes non coding RNA’s, micro RNA’s, histone modifications and DNA methylation. Increasing demand for epigenetics drugs and diagnostic technology is a direct consequence of rapidly increasing incidences of oncological disorders. Recent technological advancements in screening tools are also fuelling growth of epigenetics drugs and diagnostic technologies market. Increasing investments on research and development by various healthcare institutes and increasing incidence rate of chronic diseases such as heart diseases, diabetes and cancer are the factors further expected to fuel the epigenetics drugs and diagnostic technologies market over the forecast period. However, generalization of various major drugs is a factor expected to impede the epigenetics drugs and diagnostic technologies market over coming seven years.
The entire epigenetics drugs and diagnostic technology market is segmented on the basis of technology and mechanism of action. On the basis of mechanism of action, the market is classified into HDAC inhibitors and DNMT inhibitors. HDAC inhibitors are further divided into romidepsin (isodax) and vorinostat (zolinza). The DNMT inhibitors segment is further classified into decitabine (dacogen) and azacitidine (vidaza). The market on the basis of technology, is segmented into chromatin immunoprecipitation (ChIP) technology and DNA methylation. Increasing demand for effective cancer diagnostics is expected to fuel usage of epigentics reagents and assays thereby providing the market with lucrative growth platform.
Geographically, the overall epigenetics drugs and diagnostic technologies market is segmented into North America, Asia Pacific, Europe, Latin America and MEA. North America attributed largest share in the market owing to the increasing incidences of oncology & chronic disorders and awareness pertaining to treatment of chronic diseases caused by changing gene expressions. European market, owing to increasing geriatric population base accounted for the second largest share holder in epigenetics drugs and diagnostic technologies market. Asia Pacific is expected to witness lucrative growth over the forecast period due to rapidly improving healthcare infrastructure and presence of larger untapped opportunitie in this region.
Some key players in the global epigenetics drugs and diagnostic technologies market include Varlix Plc, Topotarget A/S, Syndax Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Promega Corporation, Novartis International AG, Oncolys BioPharma Inc., MDxHealth, Merck & Company Inc., Illumina Inc., Epizyme Inc., Envivo Pharmaceuticals Inc., Epigentek Group Inc., Chroma Therapeutics Ltd., Celleron Therapeutics Ltd., CellCentric Ltd., Astex Pharmaceuticals Inc., Acetylon Pharmaceuticals, Inc., 4SC AG, Merck, Pharmacyclics, Eisai Pharmaceuticals and Celenge. These companies are involved in continuous research and development process and are adopting various competitive strategies such as collaborations, expansions and acquisitions to gain advantage and maintain a strong position in the global epigenetics drugs and diagnostic technologies market.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.